Neurophysiological biomarkers for drug development in schizophrenia
- 1 January 2008
- journal article
- review article
- Published by Springer Science and Business Media LLC in Nature Reviews Drug Discovery
- Vol. 7 (1), 68-83
- https://doi.org/10.1038/nrd2463
Abstract
No abstract availableKeywords
This publication has 201 references indexed in Scilit:
- Activation of Cannabinoid-1 Receptors Disrupts Sensory Gating and Neuronal Oscillation: Relevance to SchizophreniaBiological Psychiatry, 2008
- Children and Adolescents with Autism Exhibit Reduced MEG Steady-State Gamma ResponsesBiological Psychiatry, 2007
- Recent Advances in the Development of Novel Pharmacological Agents for the Treatment of Cognitive Impairments in SchizophreniaSchizophrenia Bulletin, 2007
- Progressive and Interrelated Functional and Structural Evidence of Post-Onset Brain Reduction in SchizophreniaArchives of General Psychiatry, 2007
- Encoding vs. retention: Differential effects of cue manipulation on working memory performance in schizophreniaSchizophrenia Research, 2007
- Neurophysiological Endophenotypes of Schizophrenia: The Viability of Selected Candidate MeasuresSchizophrenia Bulletin, 2006
- High Gamma Power Is Phase-Locked to Theta Oscillations in Human NeocortexScience, 2006
- Heritability and Reliability of P300, P50 and Duration Mismatch NegativityBehavior Genetics, 2006
- Spatiotemporal dynamics of human object recognition processing: An integrated high-density electrical mapping and functional imaging study of “closure” processesNeuroImage, 2006
- The clinical use of P300 event related potentials for the evaluation of cholinesterase inhibitors treatment in demented patientsJournal of Neural Transmission, 2003